FSCN1 and metastatic malignant neoplasm in the lymph nodes: In HNSCC patients with lymph node metastases (T2–4N1M0), serum levels of FSCN1 were 10-fold higher than in patients without clinically confirmed regional lymph node metastases (T1–4N0M0; P < 0.05; Fig. 1A).